A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors. Blood (ASH Annual Meeting Abstracts) - Crowther, M (2013)
Abstract 3636.